Scholarlink

<p>In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX <i>ERBB2</i> mRNA score as a prognostic predictor, aiming to tailor treatment strategies. We retrospectively analyzed 94 patients treated with the THP regimen between 2010 and 2024. The HER2DX <i>ERBB2</i> mRNA score was categorized as low (<i>n</i> = 14), medium (<i>n</i> = 20), or high (<i>n</i> = 60), and its correlation with progression-free survival (PFS) and overall survival (OS) was assessed using Cox regression models. The median follow-up was 31.5 months. Patients with <i>ERBB2</i>-high scores had significantly better median PFS (33.9 vs. 10.6 months, hazard ratio [HR] = 0.40, 95% CI: 0.24–0.69, <i>p</i> &lt; 0.001) and OS (not reached vs. 30.8 months, HR = 0.26, 95% CI: 0.13–0.49, <i>p</i> &lt; 0.001) compared to <i>ERBB2</i>-low patients. Based on these findings, further validation of this biomarker in tumor samples from the CLEOPATRA phase III trial is ongoing, which could help optimize treatment strategies in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月25日

查看全文
  • Rodrigo Sánchez-Bayona,
  • Olga Martínez-Sáez,
  • Denys Romero-Romero,
  • Elia Seguí,
  • Esther Carcelero,
  • Pablo Tolosa,
  • Jesús Soberino,
  • Manuel Alva,
  • Tomás Pascual,
  • Laura Lema,
  • Isabel Garcia-Fructuoso,
  • Maria Angeles Cobos-Fernandez,
  • Maria Rey,
  • Luis Manso,
  • Angela Aguirre,
  • Ainhoa Madariaga,
  • Valeria Sirenko,
  • Cristina González-Deza,
  • Paula Blasco,
  • Astrid Mayhua,
  • Oleguer Castillo,
  • Patricia Galván,
  • Esther Sanfeliu,
  • Guillermo Villacampa,
  • Wesley Buckingham,
  • Mercedes Marín-Aguilera,
  • Laia Paré,
  • Patricia Villagrasa,
  • Charles M. Perou,
  • Julia Maues,
  • Fara Brasó-Maristany,
  • Eva Ciruelos,
  • Aleix Prat

摘要

In advanced HER2-positive breast cancer, the standard taxane-trastuzumab-pertuzumab (THP) regimen faces competition from new therapies, emphasizing the need for biomarkers to guide treatment. This study evaluates the HER2DX ERBB2 mRNA score as a prognostic predictor, aiming to tailor treatment strategies. We retrospectively analyzed 94 patients treated with the THP regimen between 2010 and 2024. The HER2DX ERBB2 mRNA score was categorized as low (n = 14), medium (n = 20), or high (n = 60), and its correlation with progression-free survival (PFS) and overall survival (OS) was assessed using Cox regression models. The median follow-up was 31.5 months. Patients with ERBB2-high scores had significantly better median PFS (33.9 vs. 10.6 months, hazard ratio [HR] = 0.40, 95% CI: 0.24–0.69, p < 0.001) and OS (not reached vs. 30.8 months, HR = 0.26, 95% CI: 0.13–0.49, p < 0.001) compared to ERBB2-low patients. Based on these findings, further validation of this biomarker in tumor samples from the CLEOPATRA phase III trial is ongoing, which could help optimize treatment strategies in this population.